Praxbind®(idarucizumab):
Immediate, complete and sustained
reversal of Pradaxa®(dabigatran etexilate)1–5
What is Praxbind® (idarucizumab)?
Praxbind® is a targeted antidote to dabigatran. As the specific reversal agent for dabigatran, Praxbind® is indicated in adult patients treated with Pradaxa® when rapid reversal of the anticoagulant effects of Pradaxa® is required.1
Why Pradaxa® reversal matters
Pradaxa® reversal with Praxbind® provides reassurance in cases of emergency surgery or urgent procedures and in instances of life-threatening or uncontrolled bleeding.1
Praxbind®: A reason
to prescribe Pradaxa®
Pradaxa® is the only NOAC with a specific reversal agent, Praxbind®, for emergency surgery/urgent procedures and life-threatening or uncontrolled bleeding. Consequently, Praxbind® provides the reassurance of immediate, complete and sustained reversal of the anticoagulant effects of Pradaxa, when required in emergency situations.1–5 As the specific reversal agent for Pradaxa®, Praxbind® is included on the National Antidote List and must be available within 1 hour to all Emergency Departments within UK hospitals.6
Praxbind® is on the UK National Antidote List and must be available within 1 hour to all Emergency Departments (i.e within the hospital)6
Immediate, complete, sustained reversal of the anticoagulant effect of Pradaxa®1-5
Easy to use with no contraindications1
No prothrombotic effect1
Fixed 5g dose for all patients - ready to use solution for IV administration1
Pradaxa® can be restarted after 24 hours, if clinically appropriate1
Praxbind® dosing and administration
Reversal of the anticoagulant effects of dabigatran is achieved with a fixed, ready-to-use IV dose of 5g Praxbind®. A fixed dose of Praxbind® ensures reversal of dabigatran for all patients. This means that you never have to worry about calculating dose adjustments according to the Pradaxa® dose administered or time since last Pradaxa® dose, or patient characteristics such as age and renal or hepatic impairment.1
Praxbind® mechanism of action
Idarucizumab is a humanised monoclonal antibody fragment (Fab) that binds to dabigatran with very high affinity - 300 times more potent than the binding affinity of dabigatran for thrombin. Idarucizumab potently and specifically binds to dabigatran and its metabolites and neutralises their anticoagulant effect, rapidly eliminating it from the body.1
Idarucizumab is specific for dabigatran and can be used together with any other supportive measures or treatments required to manage patients on Pradaxa® with life-threatening bleeding or those requiring emergency surgery.1 Praxbind® takes dabigatran out of the equation, allowing physicians to focus on other aspects of emergency patient management.
Watch the mechanism of action of Praxbind® in the video below to see how it brings about the reversal of dabigatran.
IV - Intravenous
NOAC - non-vitamin K antagonist oral anticoagulant
- Praxbind® Summary of Product Characteristics.
- Pollack CV, et al. N Engl J Med 2017;377(5):431–441.
- Schiele F, et al. Blood 2013; 121(18):3554-3562.
- Pradaxa® 150mg hard capsules Summary of Product Characteristics.
- Pradaxa® 110mg hard capsules Summary of Product Characteristics.
- Royal College of Emergency Medicine and National Poisons Information Service.
Guideline on Antidote Availability for Emergency Departments (January 2017).